Anzeige
Mehr »
Freitag, 05.09.2025 - Börsentäglich über 12.000 News
Set to Action: Q-Gold vor drastischer Neubewertung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41188 | ISIN: US5787841007 | Ticker-Symbol:
NASDAQ
04.09.25 | 22:00
15,040 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MAZE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
MAZE THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur MAZE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MAZE THERAPEUTICS Aktie jetzt für 0€ handeln
DiBTIG initiates Maze Therapeutics stock with Buy rating on kidney disease potential1
DiMaze Therapeutics names new finance chief1
DiMisbah Tahir wird neuer CFO bei Maze Therapeutics1
DiMaze Therapeutics Names Misbah Tahir As CFO1
DiMaze Therapeutics, Inc.: Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer122SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for...
► Artikel lesen
DiMaze Therapeutics, Inc. - 8-K, Current Report3
28.08.Maze Therapeutics referred to federal marketing regulators over challenge brought by Vertex24
12.08.Maze Therapeutics, Inc.: Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights88MZE782 Phase 1 Trial in Healthy Volunteers to Provide Proof of Mechanism Data for Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) Expected in Q3 2025 MZE829 Phase 2 HORIZON Trial Actively Enrolling...
► Artikel lesen
12.08.Maze Therapeutics, Inc. - 8-K, Current Report1
23.07.H.C. Wainwright startet Coverage für Maze Therapeutics mit "Buy"-Rating und Kursziel von 34 US-Dollar2
23.07.H.C. Wainwright initiates coverage on Maze Therapeutics stock with Buy rating-
14.05.Maze Therapeutics, Inc. - 10-Q, Quarterly Report1
14.05.Maze Therapeutics, Inc.: Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones146MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease; Initial Data Expected in Q1 2026 MZE782 Phase 1 Healthy Volunteer Trial Ongoing; Initial Data Expected in Q3 2025 Strong...
► Artikel lesen
31.03.Maze Therapeutics GAAP EPS of -$18.323
31.03.Maze Therapeutics, Inc.: Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights282 MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease (AKD); Initial Data Expected in Q1 2026 MZE782 Phase 1 Healthy Volunteer Trial Ongoing; Initial Data Expected in H2 2025 Raised...
► Artikel lesen
31.03.Maze Therapeutics, Inc. - 10-K, Annual Report1
31.03.Maze Therapeutics, Inc. - 8-K, Current Report1
07.02.Maze Therapeutics, Inc.: Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease290SOUTH SAN FRANCISCO, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop...
► Artikel lesen
31.01.Maze Therapeutics Prices Upsized IPO Of 8.75 Mln Shares At $16.00/shr808WASHINGTON (dpa-AFX) - Maze Therapeutics Inc. (MAZE) announced that it has priced its upsized initial public offering of 8.75 million shares of its common stock at a public offering price...
► Artikel lesen
31.01.Maze Therapeutics, Inc.: Maze Therapeutics Announces Pricing of Upsized Initial Public Offering162SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop...
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1